Latest Articles

Publication Date
Genmab takes its Profound buy into endometrial | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Genmab takes its Profound buy into endometrial | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Published: Sept. 16, 2025, 3:39 p.m.
How long does combined hormonal therapy suppress AMH levels in women with endometriomas? Results from an exploratory analysis of a clinical trial.

Lower Anti-Müllerian hormone (AMH) levels have been observed in women with ovarian endometriomas (OMA) undergoing combined hormonal contraceptive (CHC) therapy. However, the extent and timing of AMH recovery after CHC …

Published: Sept. 16, 2025, midnight
Efficacy of Elagolix and Relugolix for the Treatment of Pelvic Pain in Patients With Endometriosis: A Systematic Review.

Endometriosis is a chronic gynecological condition commonly associated with pelvic pain, dysmenorrhea, dyspareunia, and infertility. Owing to the limitations and adverse effects of traditional hormonal therapies, this study aimed to …

Published: Sept. 12, 2025, midnight
Endometriosis Pain Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine - Barchart.com

Endometriosis Pain Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Barchart.com

Published: Sept. 3, 2025, 3:30 p.m.
Endometrial Cancer Pipeline Outlook 2025 - Clinical Trials, - openPR.com

Endometrial Cancer Pipeline Outlook 2025 - Clinical Trials, openPR.com

Published: Aug. 20, 2025, 3:46 a.m.
Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences - The Globe and Mail

Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences The Globe and Mail

Published: Aug. 6, 2025, 1:11 p.m.
(PDF) Effects of standard and low doses of estradiol on markers of endometrial receptivity in frozen-thawed embryo transfer cycles: Double-blind, randomized clinical trial - researchgate.net

(PDF) Effects of standard and low doses of estradiol on markers of endometrial receptivity in frozen-thawed embryo transfer cycles: Double-blind, randomized clinical trial researchgate.net

Published: July 30, 2025, 3:19 a.m.
Relugolix in Monotherapy and Combined Therapy for the Treatment of Uterine Diseases and Its Effects on Bones: A Systematic Review.

Background: Uterine fibroids (UFs) and endometriosis are gynecological conditions that significantly increase morbidity among women of reproductive age. Relugolix, a novel gonadotropin-releasing hormone receptor antagonist, is approved in combined therapy …

Published: July 30, 2025, midnight
Disparities in Racial and Ethnic Representation in Clinical Trials for FDA-Approved Treatments of Endometriosis.

Published: July 23, 2025, midnight
Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms | DelveInsight - GlobeNewswire

Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms | DelveInsight GlobeNewswire

Published: July 15, 2025, 5:01 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!